Bruderman Asset Management LLC Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Bruderman Asset Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 105.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,944 shares of the company’s stock after buying an additional 13,336 shares during the period. Johnson & Johnson comprises 1.3% of Bruderman Asset Management LLC’s holdings, making the stock its 27th biggest holding. Bruderman Asset Management LLC’s holdings in Johnson & Johnson were worth $3,862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. boosted its position in Johnson & Johnson by 0.6% in the 2nd quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock valued at $27,242,005,000 after buying an additional 1,168,129 shares during the period. Capital World Investors lifted its position in shares of Johnson & Johnson by 182.9% in the 1st quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after purchasing an additional 13,703,905 shares during the period. Morgan Stanley lifted its position in shares of Johnson & Johnson by 0.3% in the 1st quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after purchasing an additional 54,563 shares during the period. Nordea Investment Management AB lifted its position in shares of Johnson & Johnson by 88.0% in the 2nd quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock worth $2,382,514,000 after purchasing an additional 8,062,204 shares during the period. Finally, Capital International Investors lifted its position in shares of Johnson & Johnson by 13.6% in the 1st quarter. Capital International Investors now owns 16,726,965 shares of the company’s stock worth $2,193,411,000 after purchasing an additional 2,004,688 shares during the period. 67.44% of the stock is owned by institutional investors.

In related news, EVP Ashley Mcevoy sold 29,000 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now directly owns 21,682 shares in the company, valued at $3,197,444.54. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by company insiders.

JNJ has been the subject of several research reports. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. SVB Leerink reiterated an “outperform” rating on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Bank of America reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 20th. Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Finally, Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $164.93.

NYSE:JNJ opened at $148.10 on Friday. The company’s 50-day moving average price is $148.57 and its 200-day moving average price is $146.59. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.40. The company has a market cap of $389.92 billion, a P/E ratio of 23.29, a P/E/G ratio of 3.36 and a beta of 0.68. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion for the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same period last year, the firm posted $2.12 earnings per share. On average, analysts expect that Johnson & Johnson will post 8 earnings per share for the current year.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: Bond

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Intel Co.  Shares Sold by Ziegler Capital Management LLC
Intel Co. Shares Sold by Ziegler Capital Management LLC
LexAurum Advisors LLC Has $438,000 Holdings in PepsiCo, Inc.
LexAurum Advisors LLC Has $438,000 Holdings in PepsiCo, Inc.
D. B. Root & Company LLC Has $449,000 Stock Holdings in PepsiCo, Inc.
D. B. Root & Company LLC Has $449,000 Stock Holdings in PepsiCo, Inc.
Fulcrum Asset Management LLP Makes New Investment in Pfizer Inc.
Fulcrum Asset Management LLP Makes New Investment in Pfizer Inc.
PepsiCo, Inc.  Shares Acquired by Aevitas Wealth Management Inc.
PepsiCo, Inc. Shares Acquired by Aevitas Wealth Management Inc.
Marino Stram & Associates LLC Has $2.05 Million Holdings in PepsiCo, Inc.
Marino Stram & Associates LLC Has $2.05 Million Holdings in PepsiCo, Inc.


 
© 2006-2020 Zolmax.